- Home
- MNMD vs IMTX Comparison
MNMD vs IMTX Comparison
Compare MNMD & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNMD | IMTX |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MNMD | IMTX |
|---|---|---|
| Price | $13.44 | $10.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $30.33 | $19.25 |
| AVG Volume (30 Days) | ★ 2.0M | 564.1K |
| Earning Date | 11-06-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $99,445,031.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.70 | $3.30 |
| 52 Week High | $14.43 | $12.41 |
Technical Indicators
Market Signals| Indicator | MNMD | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 49.13 |
| Support Level | $12.70 | $9.96 |
| Resistance Level | $14.28 | $10.50 |
| Average True Range (ATR) | 0.70 | 0.42 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 62.28 | 54.46 |
Price Performance
Historical ComparisonAbout MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.